Pensioenfonds Rail & OV purchased a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 6,665 shares of the company’s stock, valued at approximately $7,713,000. Eli Lilly and Company accounts for about 2.0% of Pensioenfonds Rail & OV’s investment portfolio, making the stock its 16th biggest position.
Other institutional investors have also added to or reduced their stakes in the company. Marshall & Sterling Wealth Advisors Inc. increased its position in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the period. Torren Management LLC lifted its holdings in shares of Eli Lilly and Company by 357.1% during the third quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after buying an additional 25 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $42,000. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the third quarter valued at about $49,000. Finally, Caitlin John LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $64,000. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company News Summary
Here’s some of the latest news about LLY:
- Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
- Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
- Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. HSBC raised their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday, November 9th. BMO Capital Markets reissued an “outperform” rating and issued a $1,650.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. Citigroup increased their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Bank of America reaffirmed a “buy” rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.
Get Our Latest Stock Analysis on LLY
Insider Activity at Eli Lilly and Company
In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.
Eli Lilly and Company Price Performance
Shares of NYSE LLY traded up $16.77 during mid-day trading on Friday, reaching $1,444.05. The company had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The firm has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. The business’s 50-day simple moving average is $1,242.25 and its 200 day simple moving average is $1,110.30. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.02 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
